Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

Chicago, IL – August 12, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

A Fallen Giant Pfizer (NYSE:PFE) has been a bitter pill for investors to swallow. Down 19% from its 52-week high of $30.43 per share, PFE stock has plummeted over 50% in the past three years, a stark ...

Here is why Pfizer's newfound momentum could set the stock up to soar in 2026. Pfizer's generous dividend has become a big ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

In early corporate news, GSK wins a payout after settlement is reached in the legal action between partner CureVac and BioNTech on Thursday, while Renewables Infrastructure posts a widened interim ...

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Drugmaker Viatris beat Wall Street estimates for second-quarter profit and revenue on Thursday, helped by demand for its products in China, sending its shares up nearly 5% in early trading.

The dividend yield investors could receive from Pfizer stock has risen from about 3% in early 2022 to 7% when the market ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.CEO Albert Bourla ...